Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
EP3528790A1
Pharmaceutical formulations of prasugrel and processes for the preparation thereof
WO2017108972A1
Compounds of r-(-)-(e)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1 -imidazolylacetonitrile-ha (luliconazole-ha) as antifungals
SG11201802944VA
Pregabalin compositions
WO2016142173A1
4-(2-methyl-1h-imidazol-1-yl)-2,2-diphenylbutanenitrile solid form
US2017334848A1
Process for preparing (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide
WO2016005560A1
Process for prepararing apixaban
EP2978745A1
Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
WO2014096373A1
Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
WO2013189829A1
Process for obtaining (s)-2-benzyl-4-((3ar,7as)-hexahydro-1 h-isoindol- 2(3h)-yl)-4-oxobutanoic acid and salts thereof
CN104220420A
New polymorphic form of long-acting beta-2 adrenoceptor agonist
EP2759293A1
Pharmaceutical compositions of (+)-(s)-2-(3-benzoylphenyl)propionic acid tromethamine salt
WO2013053739A1
Process for preparing factor xa inhibitors
EP2736509A1
Process for preparing prasugrel
EP2709616A1
Synthesis of a stable micronised monoclinic form of asenapine maleate
WO2012156676A1
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
GB201204418D0
New polymorphic form of a long acting beta-2 andrenoceptor agonist
EP2612658A1
Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
